Novel neurotransmitter releasers useful for cognition enhancement
CA 2128233 A1 · Owner: Du Pont Merck Pharmaceutical Company · Inventors: Earl, Richard Alan; Wilkerson, Wendell Wilkie; Voss, Matthew Ernst
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds of formula (I) have been shown to enhance the release of the neurotransmitter acetylcholine, and thus may be useful in the treatment of diseases of man, such as in Alzheimer's disease and other conditions involving learning and cognition where, subnormal levels of this neurochemical are found. The compounds of this invention can be described as shown in formula (I) where Q is (a) or (b), A and B are independently selected from the group including H, R4, -OH and -OCOR4, or A and B together form =O =S, =CH2, =CHR4, =C(R4), =NOH, =NOR4, 1,3-dioxane 1,3-dioxolane, 1,3-dithiane or 1,3-dithiolane; R1 is 4- 3-, or, 2-pyridyl, pirimidyl, pyrazinyl 2-fluoro-4-pyridyl or, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 30, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 30, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 30, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.